_version_ 1783547457388412928
author Caffo, O.
Zagonel, V.
Baldessari, C.
Berruti, A.
Bortolus, R.
Buti, S.
Ceresoli, G.L.
Donini, M.
Ermacora, P.
Fornarini, G.
Fratino, L.
Masini, C.
Massari, F.
Mosca, A.
Mucciarini, C.
Procopio, G.
Tucci, M.
Verri, E.
Zucali, P.
Buttigliero, C.
author_facet Caffo, O.
Zagonel, V.
Baldessari, C.
Berruti, A.
Bortolus, R.
Buti, S.
Ceresoli, G.L.
Donini, M.
Ermacora, P.
Fornarini, G.
Fratino, L.
Masini, C.
Massari, F.
Mosca, A.
Mucciarini, C.
Procopio, G.
Tucci, M.
Verri, E.
Zucali, P.
Buttigliero, C.
author_sort Caffo, O.
collection PubMed
description
format Online
Article
Text
id pubmed-7299865
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher European Society for Medical Oncology. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-72998652020-06-18 On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2 Caffo, O. Zagonel, V. Baldessari, C. Berruti, A. Bortolus, R. Buti, S. Ceresoli, G.L. Donini, M. Ermacora, P. Fornarini, G. Fratino, L. Masini, C. Massari, F. Mosca, A. Mucciarini, C. Procopio, G. Tucci, M. Verri, E. Zucali, P. Buttigliero, C. Ann Oncol Letter to the Editor European Society for Medical Oncology. Published by Elsevier Ltd. 2020-10 2020-06-18 /pmc/articles/PMC7299865/ /pubmed/32562741 http://dx.doi.org/10.1016/j.annonc.2020.06.005 Text en © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Caffo, O.
Zagonel, V.
Baldessari, C.
Berruti, A.
Bortolus, R.
Buti, S.
Ceresoli, G.L.
Donini, M.
Ermacora, P.
Fornarini, G.
Fratino, L.
Masini, C.
Massari, F.
Mosca, A.
Mucciarini, C.
Procopio, G.
Tucci, M.
Verri, E.
Zucali, P.
Buttigliero, C.
On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2
title On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2
title_full On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2
title_fullStr On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2
title_full_unstemmed On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2
title_short On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2
title_sort on the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by sars-cov-2
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299865/
https://www.ncbi.nlm.nih.gov/pubmed/32562741
http://dx.doi.org/10.1016/j.annonc.2020.06.005
work_keys_str_mv AT caffoo ontherelationshipbetweenandrogendeprivationtherapyforprostatecancerandriskofinfectionbysarscov2
AT zagonelv ontherelationshipbetweenandrogendeprivationtherapyforprostatecancerandriskofinfectionbysarscov2
AT baldessaric ontherelationshipbetweenandrogendeprivationtherapyforprostatecancerandriskofinfectionbysarscov2
AT berrutia ontherelationshipbetweenandrogendeprivationtherapyforprostatecancerandriskofinfectionbysarscov2
AT bortolusr ontherelationshipbetweenandrogendeprivationtherapyforprostatecancerandriskofinfectionbysarscov2
AT butis ontherelationshipbetweenandrogendeprivationtherapyforprostatecancerandriskofinfectionbysarscov2
AT ceresoligl ontherelationshipbetweenandrogendeprivationtherapyforprostatecancerandriskofinfectionbysarscov2
AT doninim ontherelationshipbetweenandrogendeprivationtherapyforprostatecancerandriskofinfectionbysarscov2
AT ermacorap ontherelationshipbetweenandrogendeprivationtherapyforprostatecancerandriskofinfectionbysarscov2
AT fornarinig ontherelationshipbetweenandrogendeprivationtherapyforprostatecancerandriskofinfectionbysarscov2
AT fratinol ontherelationshipbetweenandrogendeprivationtherapyforprostatecancerandriskofinfectionbysarscov2
AT masinic ontherelationshipbetweenandrogendeprivationtherapyforprostatecancerandriskofinfectionbysarscov2
AT massarif ontherelationshipbetweenandrogendeprivationtherapyforprostatecancerandriskofinfectionbysarscov2
AT moscaa ontherelationshipbetweenandrogendeprivationtherapyforprostatecancerandriskofinfectionbysarscov2
AT mucciarinic ontherelationshipbetweenandrogendeprivationtherapyforprostatecancerandriskofinfectionbysarscov2
AT procopiog ontherelationshipbetweenandrogendeprivationtherapyforprostatecancerandriskofinfectionbysarscov2
AT tuccim ontherelationshipbetweenandrogendeprivationtherapyforprostatecancerandriskofinfectionbysarscov2
AT verrie ontherelationshipbetweenandrogendeprivationtherapyforprostatecancerandriskofinfectionbysarscov2
AT zucalip ontherelationshipbetweenandrogendeprivationtherapyforprostatecancerandriskofinfectionbysarscov2
AT buttiglieroc ontherelationshipbetweenandrogendeprivationtherapyforprostatecancerandriskofinfectionbysarscov2